The metabolic syndrome in type 2 diabetes: When does it matter?

Aims:  Young adults with type 2 diabetes (T2Dm) present the clinician with the problem of when to start therapies for the primary prevention of vascular disease and how to identify those at most vascular risk. We examine whether the metabolic syndrome (MetS) can be a useful clinical tool to stratify...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2006-11, Vol.8 (6), p.690-697
Main Authors: Wong, J., Molyneaux, L., Constantino, M. I., Twigg, S. M., Yue, D. K.
Format: Article
Language:English
Subjects:
Adult
Age Distribution
Aged
Body Mass Index
cardiovascular disease
diabetes in youth
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - epidemiology
Diabetic Angiopathies - epidemiology
Epidemiologic Methods
Female
Humans
Insulin Resistance
macrovascular disease
Male
metabolic syndrome
Metabolic Syndrome - epidemiology
Middle Aged
Myocardial Ischemia - epidemiology
Myocardial Ischemia - etiology
New South Wales - epidemiology
Peripheral Vascular Diseases - epidemiology
Peripheral Vascular Diseases - etiology
Prognosis
risk management
Stroke - epidemiology
Stroke - etiology
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims:  Young adults with type 2 diabetes (T2Dm) present the clinician with the problem of when to start therapies for the primary prevention of vascular disease and how to identify those at most vascular risk. We examine whether the metabolic syndrome (MetS) can be a useful clinical tool to stratify vascular risk in this context. Methods:  Data were collected from 5928 subjects with T2Dm, and subjects were categorized as having MetS by World Health Organization criteria (body mass index criteria modified for Asians using >23 kg/m2). The prevalence of macrovascular disease was examined by MetS status and age. Results:  The overall MetS prevalence was 72.3%. MetS was associated with an increased prevalence of ischaemic heart disease (IHD) (17.2% MetS vs. 11.6% no MetS, p 
ISSN:1462-8902
1463-1326
DOI:10.1111/j.1463-1326.2005.00565.x